GoodRX | GDRX | Long at $5.00

Feb 14, 2025

GoodRX GDRX . Going long at $5.00.

Pros:

• Revenue is growing and is expected to reach almost $1 billion by 2027
• Debt-to-equity = 0.71x (low)
• Monthly active users continue to increase (+7% during Q3 of 2024)
• From a technical analysis perspective, the downward trend is starting to reverse, and the price has connected with my historical simple moving average (likely leading to a price increase)

Cons:

• Not yet profitable
• A lot of market competition
• Insiders exercising of options outweighs awarding of options
• No dividend

Targets:

1. $6.00
2. $7.00
3. $8.00
4. Substantially higher if partnerships emerge and profitability begins

Aug 8, 2025

Note

Added another strong position at $3.50 after the latest earnings drop. Average holding near $4.15.

Jul 2

Note

Final major entry at $2.00. New cost average is $2.99. Plan to sell out of previous entries as price rises above each or sell out entirely near the historical mean (currently near $4.75)